Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays
Abstract
Background
Seroconversion panels (SCP) are an important tool for investigating antibody responses and developing serological assays. A SCP was generated from a single SARS-CoV-2 positive plasma donor over 87 days.
Methods
This SCP was tested against five SARS-CoV-2 antibody tests (IgG, IgM and total Ig). All test kits utilized recombinant antigens that are specific to SARS-CoV-2.
Results
The SCP showed IgG responses for SARS-CoV-2 after day 50. IgM levels peaked on day 50 (prior to IgG) and declined in subsequent samples.
Conclusion
This SCP is a useful tool for validation of SARS-CoV-2 antibody assays.
Related articles
Related articles are currently not available for this article.